Evaxion Sets March 5 Date for 2025 Results and Business Update

The latest announcement is out from Evaxion Biotech ( (EVAX) ).

Evaxion A/S, a clinical-stage TechBio company listed on Nasdaq and focused on AI-driven cancer and infectious disease vaccines, announced that it will deliver a business update alongside its full-year 2025 financial results on March 5, 2026. The company’s leadership will host a conference call and webcast that day before the U.S. market opens, underscoring its efforts to engage investors and other stakeholders as it progresses its AI-Immunology-powered vaccine pipeline and broader corporate strategy.

The most recent analyst rating on (EVAX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.

Spark’s Take on EVAX Stock

According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.

The score is held back primarily by weak financial fundamentals (ongoing losses, negative free cash flow, and balance sheet instability) and bearish technicals. Offsetting these, the latest earnings call was notably positive due to the MSD deal extending runway and strong EVX-01 clinical updates, while valuation support is limited given the negative P/E and no dividend.

To see Spark’s full report on EVAX stock, click here.

More about Evaxion Biotech

Evaxion A/S is a Copenhagen-based clinical-stage TechBio company that develops novel cancer and infectious disease vaccines using its proprietary, clinically validated AI-Immunology platform. The business applies artificial intelligence to decode the human immune system, enabling rapid target discovery, drug design and development, and it is advancing both personalized and off-the-shelf vaccine candidates addressing high unmet medical needs.

Average Trading Volume: 75,781

Technical Sentiment Signal: Strong Sell

Current Market Cap: $19.96M

For a thorough assessment of EVAX stock, go to TipRanks’ Stock Analysis page.